The company will also augment related infrastructure
Piramal Enterprises' Pharma Solution division is planning to invest $40 million on new equipment and modern technologies.
"To serve our partners better, Piramal Pharma Solutions continues to invest in next generation technologies and R&D. The recent investments include areas such as anti-body drug conjugation (ADC), advanced flow reactor (ARF) and biocatalysis centre of excellence systems," the company said in a statement.
In addition to the investment, it will also augment related infrastructure. Recently, the company completed a $10 million green field facility to double its discovery services capacity, and also approved a $20 million capacity expansion for hormonal (Morpeth) and ADC (Grangemouth) manufacturing.